Colestid (colestipol hydrochloride) NDC 0009-0450

NDC codes

FDA NDC Directory

Product NDC (as listed)0009-0450Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00009-0450Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
0009-0450-03	00009045003	120 TABLET in 1 BOTTLE (0009-0450-03)Marketed from Jul 19, 1994

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Colestid
Generic name (nonproprietary): colestipol hydrochloride
Active ingredients: Colestipol hydrochloride — 1 g/1
Dosage form: Tablet
Route: Oral
Labeler: Pharmacia & Upjohn Company LLC
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 020222
Marketing start: Jul 19, 1994
Listing expires: Dec 31, 2026
Other FDA classes: Bile-acid Binding Activity (Mechanism)
Identifiers: Product ID 0009-0450_62a88ff5-632d-4fe7-a4e5-1170f1c70dd3SPL ID 62a88ff5-632d-4fe7-a4e5-1170f1c70dd3SPL set ID 3e270911-f27b-44d4-b0a2-33506418cc1dRxCUI 1048445, 1048447UNII X7D10K905GUPC 0300090450038
Pharmacologic class: Bile Acid Sequestrant

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N400009045003 followed by a unit qualifier and the quantity

Package 00009-0450-03. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Oct 24, 2024.

Indications (excerpt from the label)

INDICATIONS AND USAGE Since no drug is innocuous, strict attention should be paid to the indications and contraindications, particularly when selecting drugs for chronic long-term use. COLESTID Tablets are indicated as adjunctive therapy to diet for the reduction of elevated serum total and LDL-C in patients with primary hypercholesterolemia (elevated LDL-C) who do not respond adequately to diet. Generally, COLESTID Tablets have no clinically significant effect on serum triglycerides, but with their use, triglyceride levels may be raised in some patients. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increa…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under NDA 020222

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 020222
Product	Strength	Form · route	Labeler	Product NDC
Colestipol Hydrochloride	Colestipol hydrochloride 1 g/1	TabletOral	Mylan Pharmaceuticals Inc.	59762-0450